Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio angiogenesis trial (KAT)

Circulation

Volumn 107, Issue 21, 2003, Pages 2677-2683

  Hedman, Marja ^a,b   Hartikainen, Juha ^b   Syvänne, Mikko ^c   Stjernvall, Joachim ^c   Hedman, Antti ^b   Kivelä, Antti ^b   Vanninen, Esko ^b   Mussalo, Hanna ^b   Kauppila, Esa ^b   Simula, Sakari ^b   Närvänen, Outi ^a   Rantala, Arto ^b   Peuhkurinen, Keijo ^b   Nieminen, Markku S ^c   Laakso, Markku ^b   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angioplasty; Cardiovascular diseases; Gene therapy; Perfusion; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOSOME; NITRATE; PLACEBO; RINGER LACTATE SOLUTION; STATINE DERIVATIVE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTHROPATHY; ARTICLE; BENIGN TUMOR; BLEEDING; CARCINOMA; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FALSE ANEURYSM; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE TRANSFER; HEART ARREST; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

EID: 0038210219     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.0000070540.80780.92     Document Type: Article

References (25)

1. Ylä-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet. 2000;355:213-222.
2. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990;249:1285-1288.
3. Laitinen M, Pakkanen T, Luoma J, et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of plasmid-liposome complexes, retroviruses, pseudotyped retroviruses and adenoviruses. Hum Gene Ther. 1997;9:1645-1650.
4. Laitinen M, Zachary I, Breier G, et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 1997;8:1737-1744.
5. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123.
6. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998;98:2800-2804.
7. Rosengart TK. Lee LY. Patel SR. Angiogenesis gene therapy: phase 1 assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA in individuals with clinically significant coronary artery disease. Circulation. 1999;100:468-474.
8. Laitinen M, Mäkinen K, Manninen H, et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischaemia. Hum Gene Ther. 1998;9:1481-1486.
9. Laitinen M, Hartikainen J, Hiltunen MO, et al. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty. Hum Gene Ther. 2000;11:263-270.
10. Mäkinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase 11 study. Mol Ther. 2002;6:1-7.
11. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet. 1999;354:1493-1498.
12. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297.
13. 165 plasmid in patients with inoperable angina pectoris. Coron Artery Dis. 2001;12:239-243.
14. Kutryk MJB, Foley DP, van der Brand M, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis. J Am Coll Cardiol. 2002;39:281-287.
15. Narins CR, Holmes DR, Topol EJ. A call for provisional stenting: the balloon is back! Circulation. 1998;97:1298-1305.
16. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Hearth J. 2001;22:2125-2130.
17. Bräsen JH, Kivelä A, Röser K, et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arterioscler Thromb Vasc Biol. 2001;21:1720-1726.
18. Hiltunen MO, Laitinen M, Turunen M, et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulotiom. 2000;102:2262-2268.
19. Puumalainen A-M, Vapalahti M, Agrawal R, et al. β-Galactosidase gene transfer to human malignant glionia in vivo using replication-deficient retroviruses and adenoviruses. Hum Gente Ther. 1998;9:1769-1774.
20. Syvänne M, Nieminen MS, Frick H. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery: a validation study, Int J Card Imaging. 1994;10:243-252.
21. Simula S, Lakka T, Kuikka J, et al. Cardiac adrenergic innervation within the first 3 months after acute myocardial infarction. Clin Physiol. 2000;5:366-373.
22. Berman D, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise Technetium-99 m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol. 1995;26:639-647.
23. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359-1365.
24. Sanborn TA, Hackett NR, Lee LY, et al. Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Catheter Cardiovasc Interv. 2001;52:260-266.
25. Cancer Society of Finland. Cancer Incidence in Finland: 1996-1997. Cancer Statistics of the National Research and Development Centre for Welfare and Health. Publication No. 61. Helsinki, Finland: Cancer Society of Finland; 2000.